Pfizer, Sangamo Therapeutics and hemophilia

Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact
Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer Inc. terminated a hemophilia A gene-therapy partnership.
Pfizer kills hemophilia gene therapy deal, imperiling Sangamo
Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.
Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal
Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% in extended trade. Sangamo added that it has now regained the rights to the therapy's development and would explore all options to advance the program,
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:PFE).
Pfizer Ends Sangamo Partnership for Hemophilia Therapy
Sangamo Therapeutics said it will regain rights to develop and commercialize a therapy for hemophilia A after Pfizer terminated their collaboration and license agreement. Sangamo and Pfizer together developed the treatment,
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership
The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator.
Hosted on MSN12h
Pfizer: 4 Reasons to Buy This Stock
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to ...
Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlement
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
3 Reasons to Buy Pfizer Stock Like There's No Tomorrow
The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...
Pfizer Faces Multiple Lawsuits Over Recalled Sickle-Cell Medication
"Federal law requires defendants to ensure that their drug labels remain accurate, and when new scientific information ...
Claims that judge overseeing Mangione’s case is married to former Pfizer executive are missing context
A judge who is married to a former Pfizer executive is overseeing Mangione’s federal pretrial hearings. But she won’t oversee ...
Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.
At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...
Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked
Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.
Options running thin for longtime Sangamo Therapeutics after Pfizer deals crashes
Abrupt end of Pfizer's hemophilia A gene therapy deal with Sangamo is the latest in a line of flip-flops between the big drug ...